The Dissemination of NDM-1 in Acinetobacter baumannii Strains

Liu, Na; Zheng, Xin; Zhu, Qianhui; He, Zilong; Hu, Songnian

doi:10.1007/s00284-022-02812-w

Cited by 6 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…baumannii NDM-1 producers were first detected in 2010 in India [11]. Thereafter, many reports from various parts of the world have highlighted the appearance and the dissemination of such strains internationally [11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26]32]. A. baumannii exhibits remarkable genetic plasticity, allowing the organism to acquire resistance genes through horizontal gene transfer.…”

Section: Discussionmentioning

confidence: 99%

The Molecular Characterization of blaNDM-1-Positive Acinetobacter baumannii Isolated in Central Greece

Tsilipounidaki,

Gkountinoudis,

Florou

et al. 2023

Microorganisms

View full text Add to dashboard Cite

The objective of the present study is to report the detection and the molecular characterization of nine blaNDM-1-positive Acinetobacter baumannii isolates, which were isolated from patients in a tertiary care hospital in Central Greece from December 2022 to August 2023. The isolates were characterized by whole genome sequencing to obtain Pasteur multilocus sequencing typing (MLST) and to identify the blaNDM-1-environment, resistome, and virulence genes content. In silico MLST analysis showed that the isolates belonged to four different clones (STs 160, 2, 85, and 2493). All strains, apart from the blaNDM-1-gene, possessed at least eight different genes, encoding resistance to various antimicrobial agents. Whole genome sequencing revealed two different structures of the blaNDM-1 environment. The first, detected in ST160 strain, was identical with the Tn125, whereas the second, found in STs 2, 85, and 2493 was associated with Tn7382. To our knowledge, after a sole strain reported in 2016 and imported by a patient hospitalized in a Libyan hospital, this is the first report of the emergence of polyclonal blaNDM-1-positive Acinetobacter baumannii in Greece. Our findings re-emphasize the need to apply diligent surveillance protocols in order to limit the horizontal transfer of the blaNDM-1 gene to other A. baumannii clones or to other recipient strains.

show abstract

Section: Discussionmentioning

confidence: 99%

The Molecular Characterization of blaNDM-1-Positive Acinetobacter baumannii Isolated in Central Greece

Tsilipounidaki,

Gkountinoudis,

Florou

et al. 2023

Microorganisms

View full text Add to dashboard Cite

show abstract

“…Carbapenemase enzymes encoded by genes can be classified into molecular classes such as class A [e.g., Klebsiella pneumoniae carbapenemase ( bla KPC )], class B [e.g., Active-on-Imipenem ( bla IMP ), New Delhi metallo-β-lactamase ( bla NDM ), and Verona integron-encoded metallo-β-lactamase ( bla VIM )], and class D [e.g., Oxacillinase ( bla OXA-23-like , bla OXA-24/40-like , bla OXA-48-like , and bla OXA-58-like )]. Varying frequencies of these carbapenemases genes in A. baumannii have been reported globally, with class D carbapenemase genes most often detected ( 12 – 15 ). However, there is a lack of data describing CRAB antimicrobial susceptibility profiles by class and the frequencies of specific class D subgroups detected among CRAB from across the United States.…”

Section: Introductionmentioning

confidence: 99%

Descriptive analysis of targeted carbapenemase genes and antibiotic susceptibility profiles among carbapenem-resistant Acinetobacter baumannii tested in the Antimicrobial Resistance Laboratory Network—United States, 2017–2020

Sabour,

Bantle,

Bhatnagar

et al. 2024

Microbiol Spectr

View full text Add to dashboard Cite

Acinetobacter baumannii is a Gram-negative bacillus that can cause severe and difficult-to-treat healthcare-associated infections. A. baumannii can harbor mobile genetic elements carrying genes that produce carbapenemase enzymes, further limiting therapeutic options for infections. In the United States, the Antimicrobial Resistance Laboratory Network (AR Lab Network) conducts sentinel surveillance of carbapenem-resistant Acinetobacter baumannii (CRAB). Participating clinical laboratories sent CRAB isolates to the AR Lab Network for characterization, including antimicrobial susceptibility testing and molecular detection of class A ( Klebsiella pneumoniae carbapenemase), class B (Active-on-Imipenem, New Delhi metallo-β-lactamase, and Verona integron-encoded metallo-β-lactamase), and class D (Oxacillinase, bla OXA-23-like , bla OXA-24/40-like , bla OXA-48-like , and bla OXA-58-like ) carbapenemase genes. During 2017‒2020, 6,026 CRAB isolates from 45 states were tested for targeted carbapenemase genes; 1% (64 of 5,481) of CRAB tested for targeted class A and class B genes were positive, but 83% (3,351 of 4,041) of CRAB tested for targeted class D genes were positive. The number of CRAB isolates carrying a class A or B gene increased from 2 of 312 (<1%) tested in 2017 to 26 of 1,708 (2%) tested in 2020. Eighty-three percent (2,355 of 2,846) of CRAB with at least one of the targeted carbapenemase genes and 54% (271 of 500) of CRAB without were categorized as extensively drug resistant; 95% (42 of 44) of isolates carrying more than one targeted gene had difficult-to-treat susceptibility profiles. CRAB isolates carrying targeted carbapenemase genes present an emerging public health threat in the United States, and their rapid detection is crucial to improving patient safety. IMPORTANCE The Centers for Disease Control and Prevention has classified CRAB as an urgent public health threat. In this paper, we used a collection of >6,000 contemporary clinical isolates to evaluate the phenotypic and genotypic properties of CRAB detected in the United States. We describe the frequency of specific carbapenemase genes detected, antimicrobial susceptibility profiles, and the distribution of CRAB isolates categorized as multidrug resistant, extensively drug-resistant, or difficult to treat. We further discuss the proportion of isolates showing susceptibility to Food and Drug Administration-approved agents. Of note, 84% of CRAB tested harbored at least one class A, B, or D carbapenemase genes targeted for detection and 83% of these carbapenemase gene-positive CRAB were categorized as extensively drug resistant. Fifty-four percent of CRAB isolates without any of these carbapenemase genes detected were still extensively drug-resistant, indicating that infections caused by CRAB are highly resistant and pose a significant risk to patient safety regardless of the presence of one of these carbapenemase genes.

show abstract

An outbreak of severe or lethal infections by a multidrug-resistant Acinetobacter baumannii ST126 strain carrying a plasmid with blaNDM-1 and blaOXA-58 carbapenemases

Gutiérrez,

Vásquez-Mendoza,

Rodríguez

2024

Diagnostic Microbiology and Infectious Disease

View full text Add to dashboard Cite

The Dissemination of NDM-1 in Acinetobacter baumannii Strains

Cited by 6 publications

References 20 publications

The Molecular Characterization of blaNDM-1-Positive Acinetobacter baumannii Isolated in Central Greece

The Molecular Characterization of blaNDM-1-Positive Acinetobacter baumannii Isolated in Central Greece

Descriptive analysis of targeted carbapenemase genes and antibiotic susceptibility profiles among carbapenem-resistant Acinetobacter baumannii tested in the Antimicrobial Resistance Laboratory Network—United States, 2017–2020

An outbreak of severe or lethal infections by a multidrug-resistant Acinetobacter baumannii ST126 strain carrying a plasmid with blaNDM-1 and blaOXA-58 carbapenemases

Contact Info

Product

Resources

About